Incidence of Extensively Drug-Resistant Tuberculosis Resistance Pattern in Multidrug-Resistant Tuberculosis Isolates of Private versus Public Sector
DOI:
https://doi.org/10.46568/bios.v6i1-2.224Keywords:
XDR resistance, MDR- TB, Incidence, microbiology, patientAbstract
Tuberculosis is an ongoing dilemma in Pakistan and the Southern part of Asia. It has become a main part and parcel of research and further management in Pulmonology and Chest Medicine. Newer researches are focused on newer drugs and their efficacy on different strains of tuberculosis. Different resistance patterns and need of newer class of anti-tuberculosis drugs are talk of the town and need vigilant attention for further better management of this disease. To evaluate incidence of Extensively Drug-Resistant (XDR) resistance pattern in Multidrug-Resistant Tuberculosis (MDR-TB) isolates of private versus public sector. The study is comparative and retrospective cohort study; eighty patients were recruited for the study and split into two groups: group 1, which included forty MDR-TB stock cultures from the Laboratory of Microbiology, BMSI, and group 2, which included forty culture-positive specimens from JPMC and the Ojha Institute of Chest Diseases, Karachi. The XDR resistance pattern of these samples was examined. In accordance with WHO standards from 2021, the indirect percentage technique was employed for medication susceptibility. Results revealed that total 3.75% of patients showed extensively drug resistant resistance pattern among the MDR isolates, out of 80 patients. In group 1, none of the patients showed XDR resistance pattern while the 3 patients showing XDR pattern were from group 2, which were from Public Sector. Hence it is concluded, the XDR resistance pattern among isolates of MDR TB was higher in public sector hospital as compared to the private sector.
References
Mohan K, Alam A, Patnaik R. Prevalence and patterns of drug-resistant tuberculosis in India: evidence from the last 2.5 decades. Annals of the Romanian Society for Cell Biology. 2021;25(4):754-78.
Thomsen J, Abdulrazzaq NM, Nyasulu PS, Al Hosani F, Habous M, Weber S, Jabeen F, UAE AMR Surveillance Consortium, Menezes GA, Moubareck CA, Senok A. Epidemiology and antimicrobial resistance of Mycobacterium spp. in the United Arab Emirates: a retrospective analysis of 12 years of national antimicrobial resistance surveillance data. Frontiers in Public Health. 2024 Jun 14;12:1244353.
Faye LM, Hosu MC, Apalata T. Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Study of Patients’ Characteristics in Selected Healthcare Facilities. International Journal of Environmental Research and Public Health. 2024 Nov 30;21(12):1594.
Bhanushali A, Atre S, Nair P, Thandaseery GA, Shah S, Kuruwa S, Zade A, Nikam C, Gomare M, Chatterjee A. Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases. Microbiology Spectrum. 2024 May 2;12(5):e02770-23.
Kamolwat P, Nateniyom S, Chaiprasert A, Disratthakit A, Mahasirimongkol S, Yamada N, Smithtikarn S. Prevalence and associated risk factors of drug‐resistant tuberculosis in Thailand: results from the fifth national anti‐tuberculosis drug resistance survey. Tropical Medicine & International Health. 2021 Jan;26(1):45-53.
Rahman SM, Samina P, Rahman T, Adel AS, Nasrin R, Uddin MK, Hasan MJ, Ahmed S, Daru P, Modak PK, Salim MA. Isoniazid resistance pattern among pulmonary tuberculosis patients in Bangladesh: An exploratory study. Clinical Microbiology and Infection. 2025 Feb 1;31(2):220-5.
Farhat M, Cox H, Ghanem M, Denkinger CM, Rodrigues C, Abd El Aziz MS, Enkh-Amgalan H, Vambe D, Ugarte-Gil C, Furin J, Pai M. Drug-resistant tuberculosis: a persistent global health concern. Nature Reviews Microbiology. 2024 Oct;22(10):617-35.
Olabiyi OE, Okiki PA, Adarabioyo MI, Adebiyi OE, Adegoke OE, Esan OE, Idris OO, Agunbiade TB. Distribution of multi-drug resistant tuberculosis in Ekiti and Ondo states, Nigeria. New Microbes and New Infections. 2023 Oct 1;55:101192.
Nnanna J, Ikegbunam M, Nnanna P, Okoye E, Esimone C. SEROTYPES AND ANTIBIOTIC SUSCEPTIBILITY PATTERNS OF OPTOCHIN RESISTANT STREPTOCOCCUS PNEUMONIAE FROM ADULTS IN NIGERIA. International Journal of Infectious Diseases. 2023 Aug 1;134:S3-4.
Sylverken AA, Kwarteng A, Twumasi-Ankrah S, Owusu M, Arthur RA, Dumevi RM, Adu-Amoah L, Addofoh N, Okyere PB, Dzata F, Bonsu F. The burden of drug resistance tuberculosis in Ghana; results of the First National Survey. PLoS One. 2021 Jun 10;16(6):e0252819.
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Torrico MM, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases. 2020 Mar 1;92:S15-25.
Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C. Recent controversies about MDR and XDR‐TB: G lobal implementation of the WHO shorter MDR‐TB regimen and bedaquiline for all with MDR‐TB?. Respirology. 2018 Jan;23(1):36-45.
Faksri K, Kaewprasert O, Ong RT, Suriyaphol P, Prammananan T, Teo YY, Srilohasin P, Chaiprasert A. Comparisons of whole-genome sequencing and phenotypic drug susceptibility testing for Mycobacterium tuberculosis causing MDR-TB and XDR-TB in Thailand. International journal of antimicrobial agents. 2019 Aug 1;54(2):109-16.
Tasnim T, Tarafder S, Alam FM, Sattar H, Kamal SM. Pre-extensively drug resistant tuberculosis (Pre-XDR-TB) among pulmonary multidrug resistant tuberculosis (MDR-TB) patients in Bangladesh. Journal of Tuberculosis Research. 2018 Jul 23;6(3):199-206.
Bhering M, Duarte R, Kritski A. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016. PloS one. 2019 Nov 20;14(11):e0218299.
Siddiqui S, Brooks MB, Malik AA, Fuad J, Nazish A, Bano S, Becerra MC, Hussain H. Evaluation of GenoType MTBDR plus for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Karachi, Pakistan. PloS one. 2019 Aug 19;14(8):e0221485.
Khan FU, Khan A, Khan FU, Hayat K, Chang J, Khalid W, Noor S, Khan A, Fang Y. Assessment of adverse drug events, their risk factors, and management among patients treated for multidrug-resistant TB: A prospective cohort study from Pakistan. Frontiers in Pharmacology. 2022 May 17;13:876955.
Massud A, Khan AH, Syed Sulaiman SA, Ahmad N, Shafqat M, Ming LC. Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan. PloS one. 2023 Aug 10;18(8):e0287966.
Tasnim T, Tarafder S, Alam FM, Sattar H, Kamal SM. Pre-extensively drug resistant tuberculosis (Pre-XDR-TB) among pulmonary multidrug resistant tuberculosis (MDR-TB) patients in Bangladesh. Journal of Tuberculosis Research. 2018 Jul 23;6(3):199-206.
Abubakar M, Ahmad N, Atif M, Khan AH, Ghafoor A. Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan. ERJ Open Research. 2022 Jan 1;8(1).
Saifullah A, Mallhi TH, Khan YH, Iqbal MS, Alotaibi NH, Alzarea AI, Rasheed M. Evaluation of risk factors associated with the development of MDR-and XDR-TB in a tertiary care hospital: a retrospective cohort study. PeerJ. 2021 Mar 18;9:e10826.
Munir MK, Rehman S, Iqbal R. Meeting the challenge, making a difference: Multidrug resistance tuberculosis in Pakistan. Pakistan Journal of Medical Research. 2018;57(1):1-2.
ul Manan MA, Naqvi S, Mushtaq A, Shafqat M. Prevalence of Pre-XDR-TB and XDR-TB among MDR-TB patients. Pakistan Journal of Chest Medicine. 2018;24(4):208-11.
Sheikh AS, Aziz M, Ayaz M. Rising trends of multidrug resistant (MDR) tuberculosis in Pakistan. Biomedical Journal. 2018;1:4.
Ahmed S, Lotia-Farrukh I, Khan PY, Adnan S, Sodho JS, Bano S, Siddiqui MR, Ghafoor A, Isani AK, Salahuddin N, Khan U. High prevalence of multidrug-resistant TB among household contacts in a high burden setting. The International Journal of Tuberculosis and Lung Disease. 2023 Aug;27(8):646.
Naidoo K, Perumal R, Cox H, Mathema B, Loveday M, Ismail N, Omar SV, Georghiou SB, Daftary A, O'Donnell M, Ndjeka N. The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience. The Lancet Infectious Diseases. 2024 Mar 22.
Dixit A, Freschi L, Vargas R, Gröschel MI, Nakhoul M, Tahseen S, Alam SM, Kamal SM, Skrahina A, Basilio RP, Lim DR. Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning. BMJ Global Health. 2024 Mar 1;9(3):e013532.
Akalu GT, Tessema B, Sinshaw W, Amare M, Diriba G, Getu M, Zerihun B, Petros B. Epidemiology of first-and second-line anti-tuberculosis drug resistance in new pulmonary tuberculosis cases in Addis Ababa metropolitan area, Ethiopia. medRxiv. 2023 Apr 25:2023-04.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Hina Faisal, Azra Idris, Hira Zafar Siddiqui, Marvi, Zumrud momin, Naseha Mushtaq, Sana Tariq
This work is licensed under a Creative Commons Attribution 4.0 International License.
